Canopy
The next generation, reusable N95 - for the world’s well-being.
Overview
Raised: $21,643
Total Commitments ($USD)
StartEngine
12/30/2022
03/29/2023
$245
Equity - Common
Seed
RegCF
$5.56
$10,003,997
Rolling Commitments ($USD)
04/02/2023
$243
28
2020
Healthcare & Pharmaceuticals
HealthTech
B2B/B2C
Medium
High
Summary Profit and Loss Statement
| FY 2021 | FY 2020 | |
|---|---|---|
|
Revenue |
$74,052 |
$0 |
|
COGS |
$36,263 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-846,793 |
$-522,685 |
Summary Balance Sheet
| FY 2021 | FY 2020 | |
|---|---|---|
|
Cash |
$211,630 |
$126,035 |
|
Accounts Receivable |
$4,662 |
$0 |
|
Total Assets |
$630,267 |
$289,694 |
|
Short-Term Debt |
$50,891 |
$190,813 |
|
Long-Term Debt |
$1,101,875 |
$296,566 |
|
Total Liabilities |
$1,152,766 |
$487,379 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Updates
KingsCrowd rated Canopy a Neutral Deal during its last raise, which closed in June 2021. At the time, Canopy raised $330,013 at a $6.5 million valuation. Two years later, the company is raising again. The market is different now. Most Americans are not wearing masks anymore. But COVID is still infecting people, and healthcare professionals are still protecting themselves against it. Despite a change in the consumer market, Canopy is showing fair progress.